ABT - Abbott Laboratories
| Previous Close | 63.43 |
| Open | 63.45 |
| Bid | 62.50 x 800 |
| Ask | 63.99 x 3100 |
| Day's Range | 63.45 - 63.67 |
| 52 Week Range | 48.58 - 65.90 |
| Volume | 97,035 |
| Avg. Volume | 4,993,750 |
| Market Cap | 111.487B |
| Beta | 1.75 |
| PE Ratio (TTM) | 121.74 |
| EPS (TTM) | 0.52 |
| Earnings Date | Oct 16, 2018 - Oct 22, 2018 |
| Forward Dividend & Yield | 1.12 (1.73%) |
| Ex-Dividend Date | 2018-07-12 |
| 1y Target Est | 71.00 |
Markit•5 days agoSee what the IHS Markit Score report has to say about Abbott Laboratories.
Abbott Laboratories NYSE:ABT
Market Realist•7 days agoWhat to Expect for Boston Scientific in Fiscal 2018
During its Q2 2018 earnings release on July 25, Boston Scientific (BSX) updated its fiscal 2018 guidance. The company raised its fiscal 2018 sales guidance and maintained its adjusted EPS guidance at $1.37–$1.41, representing growth of 9%–12%.
- Market Realist•8 days ago
What Analysts Expect from Haemonetics in Q1 2019
Haemonetics (HAE) is a leading healthcare company in blood management solutions. Its devices portfolio includes surgical and diagnostic devices as well as blood and plasma center devices. The software portfolio includes blood center software, plasma center software, and hospital software.
Market Realist•8 days agoHologic Expects Robust Earnings Growth for Fiscal 2018
In its fiscal third-quarter conference call, Hologic (HOLX) narrowed the projected range of its fiscal 2018 EPS from $2.22–$2.27 to $2.24–$2.26. Considering the midpoint of the updated EPS guidance range, the company expects YoY (year-over-year) EPS growth of ~10.8% for fiscal 2018.
Market Realist•11 days agoHologic Raised Its Revenue Guidance for Fiscal 2018
During its fiscal third quarter conference call, Hologic (HOLX) raised its fiscal 2018 non-GAAP revenue guidance from $3.18 billion–$3.21 billion to ~$3.21 billion–$3.22 billion. So, its YoY (year-over-year) reported revenue growth rate for fiscal 2018 is expected to be 4.8%–5.3%, higher than the previously projected range of 4.0%–4.9%.
- Market Realist•11 days ago
Analysts’ Recommendations for Hologic and Its Peers in August
In the fiscal third quarter, Hologic reported non-GAAP EPS of ~$0.58, which was a YoY rise of 16.0%. Hologic surpassed its revenue and EPS guidance for the fiscal third quarter. Hologic’s Diagnostics business posted a recovery compared to the fiscal second quarter, and its Surgical business has posted gradual improvement since the fiscal first quarter.
Market Realist•11 days agoBoston Scientific’s Q2 2018 Adjusted EPS Exceed Guidance
In the second quarter, Boston Scientific’s adjusted EPS grew 28% YoY (year-over-year) to $0.41, exceeding its guidance of $0.33–$0.35. Boston Scientific’s strong earnings growth in the quarter was due to its strong profit and loss metrics. The company is working on improving cost efficiencies through its end-to-end business by streamlining and automation initiatives, expanding global shared services, and leveraging global sourcing teams. Peers Abbott Laboratories (ABT), Edwards Lifesciences (EW), and Thermo Fisher Scientific (TMO) reported adjusted EPS growth of 17.7%, 30.5%, and 19. ...
Market Realist•11 days agoCan Boston Scientific Maintain Its Strong Sales Momentum?
On July 25, Boston Scientific (BSX) released its Q2 2018 earnings results. It reported revenue of $2.49 billion, exceeding Wall Street’s estimate of ~$2.46 billion and coming in at the higher end of the company’s $2.45 billion–$2.5 billion guidance.
Market Realist•11 days agoWhat Analysts Recommend for Boston Scientific, Post-Q2 Results
Boston Scientific (BSX) announced its Q2 2018 results on July 25, exceeding analysts’ estimates. That day, BSX stock rose ~2.2%, while the iShares US Medical Devices ETF (IHI) rose ~1.4%. BSX comprises ~4.7% of IHI.
- PR Newswire•12 days ago
Abbott Expands its Directional Deep Brain Stimulation Therapy by Offering New MR-Conditional Labeling
- FDA approval of new software upgrade for Abbott's deep brain stimulation therapy enables advanced, patient-centric features for people living with Parkinson's disease and essential tremor - New Informity™ ...
- Motley Fool•12 days ago
What DexCom Just Said About Its Future
Sales momentum for the maker of continuous monitors for diabetes patients could accelerate.
ETF Database•12 days agoTrending: Automakers Breathe Sigh of Relief over U.S.-EU Trade Ceasefire
Shares of automotive companies climbed last Thursday as U.S. President Donald Trump eased the car tariff threat following a meeting with European Commission President Jean-Claude Juncker.
Market Realist•13 days agoAbbott Laboratories’ Stock Price Performance in July
On July 24, Abbott Laboratories (ABT) ended the trading day at $64.40 per share. Currently, the stock is trading higher than its 50-day moving average of $62.45 and its 200-day moving average of $60.75.
Market Realist•13 days agoWhat to Expect from Abbott Laboratories in Fiscal 2018
During Abbott Laboratories’ (ABT) second-quarter earnings release on July 18, the company increased its fiscal 2018 guidance. This move was triggered by the company’s strong performance in the quarter. ABT stock rose ~3.1% on the day of its earnings announcement.
- Market Realist•14 days ago
Analysts’ Recommendations for DaVita
As discussed previously, analysts expect DaVita (DVA) to post revenue of $2.877 billion, adjusted net income of ~$175.97 million, and non-GAAP EPS of ~$0.97 in Q2 2018. Of the ten analysts tracking DaVita, five recommend “strong buy,” four recommend “hold,” and one recommends “sell.”
Market Realist•14 days agoHow the Freestyle Libre CGM Opportunity Is Playing Out for ABT
Abbott Laboratories’ (ABT) Diabetes segment registered second-quarter sales growth of ~40.0%, reaching $470.0 million. The Diabetes segment’s strong performance was driven by the continued uptake of Abbott’s Freestyle Libre CGM (continuous glucose monitoring) device. The device was approved by the FDA in September 2017. Abbott Laboratories gained market share in the second quarter in the diabetes market space from competitors such as Medtronic (MDT) and Dexcom (DXCM) due to the strong momentum in its Freestyle Libre adoption.
Market Realist•14 days agoWhat Subdued ABT’s Medical Devices Segment in Q2 2018?
Q2 Results: What Drove Its Robust Growth? Abbott Laboratories (ABT) reported robust second-quarter revenues in its Medical Devices segment, as we discussed in the previous article. ABT’s heart failure and neuromodulation sales rose ~1.0%, and ~5.8%, respectively, in the second quarter on an organic basis.
Markit•14 days agoSee what the IHS Markit Score report has to say about Abbott Laboratories.
Abbott Laboratories NYSE:ABT
Market Realist•14 days agoThe Major Growth Drivers for ABT’s Medical Devices Business
Q2 Results: What Drove Its Robust Growth? The Medical Devices segment’s sales registered YoY (year-over-year) growth of ~11.3% on a reported basis. On an organic basis, the segment’s sales were up ~8.2%.
- TheStreet.com•14 days ago
Sector Rotation Is Powerful: This Tech Hit Is a Great Trade
Over the last few days, we have heard and seen all sorts of creative investment basket acronyms in the tech sector from FAANG to FAANGMA, or the new AGMA (ok, I just made that one up). It does not change the fact that everyone and their mom was invested in the tech sector, given its phenomenal growth of around 30% in large-cap companies of about $100 billion or larger. Netflix dropped 15% on weak subscriber numbers.
Market Realist•15 days agoAbbott Laboratories’ Nutrition Sales Recovered in Q2 2018
In the second quarter, Abbott Laboratories (ABT) reported sales of $1.9 billion in its Nutrition business, which contributed ~24.0% to the company’s total sales of $7.8 billion in the quarter. The Nutrition segment’s sales registered YoY (year-over-year) growth of ~7.3% on a reported basis. In the second quarter, Abbott Laboratories’ international nutrition sales came in at $1.1 billion, up ~12.5% on a YoY basis.
Market Realist•15 days agoABT Saw 12.3% Growth in Established Pharmaceuticals Segment
Q2 Results: What Drove Its Robust Growth? The Established Pharmaceuticals segment sales registered YoY (year-over-year) growth of ~10.5% on a reported basis. Foreign exchange had a negative impact of ~1.8% on the business.
Market Realist•15 days agoHow ABT’s Diagnostics Business Performed in Q2 2018
In the second quarter, Abbott Laboratories (ABT) reported sales of $1.9 billion in its Diagnostics business, which contributed ~24.0% to the company’s total sales of $7.8 billion in the quarter. The Diagnostic segment’s sales registered YoY (year-over-year) growth of ~47.2% on a reported basis. On an organic basis, the segment’s sales were up ~6.6%.
- American City Business Journals•18 days ago
Wichita hospital selected for medical device clinical trial
This places Via Christi — and Wichita for that matter — on the leading edge of a technology that eventually could be taken to market and possibly become a standard of care in cardiology.
- PR Newswire•18 days ago
Abbott's FreeStyle® Libre 14 Day Flash Glucose Monitoring System Now Approved in U.S.
ABBOTT PARK, Ill., July 27, 2018 /PRNewswire/ -- Abbott (ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the FreeStyle® Libre 14 day Flash Glucose Monitoring system, which allows people with diabetes to wear the sensor up to 14 days with high accuracy. "At Abbott, we are continuously pushing for new innovations that minimize the daily burden of managing diabetes," said Jared Watkin, senior vice president, Diabetes Care, Abbott.
